, Volume 197, Issue 1, pp 29–35 | Cite as

High Serum Fractalkine/CX3CL1 in Patients with Chronic Obstructive Pulmonary Disease: Relationship with Emphysema Severity and Frequent Exacerbation

  • Wendong HaoEmail author
  • Manxiang Li
  • Cailian Zhang
  • Yunqing Zhang
  • Yani Xue



The purpose of this study was to investigate the relationship between serum fractalkine (CX3CL1/FKN) level and the multi-slice spiral computed tomography (MSCT) emphysema index in Chinese patients with chronic obstructive pulmonary disease (COPD).


We detected chemokine CX3CL1 in serum from 95 Chinese patients with COPD by using an enzyme-linked immunosorbent assay. According to the MSCT emphysema index, the selected cases were divided into an emphysema-dominant group (n = 25) and a non-emphysema-dominant group (n = 70).


There were significant differences in body mass index and lung function between the two groups. The serum level of CX3CL1 in the emphysema-dominant group was significantly higher than that in the non-emphysema-dominant group. Through multivariate logistic regression analysis, it was found that high serum CX3CL1 levels were independently associated with emphysema, with a relative risk of 2.617 (95% CI 1.018–6.121; P = 0.029). The percentage of frequent acute exacerbations during the first year of follow-up was significantly higher in the high-level serum CX3CL1 group (P = 0.039). After 3 years of follow-up, there was no significant difference in the CT emphysema index between the high and low serum CX3CL1 groups (P = 0.503).


Our results suggest that the serum level of CX3CL1 is related to the MSCT emphysema index. Chemokine CX3CL1 might be a useful predictor for identifying frequent exacerbation and emphysema severity in patients with COPD.


CX3CL1 Emphysema Frequent exacerbation CT emphysema index Chronic obstructive pulmonary disease 


Compliance with Ethical Standards

Conflict of interest

All authors declare no conflicts of interest.


  1. 1.
    Kunisaki K, Dransfield M, Anderson J, Brook R, Calverley P, Celli B, Crim C, Hartley B, Martinez F, Newby D, Pragman A, Vestbo J, Yates J, Niewoehner D (2018) Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med 198(1):51–57CrossRefGoogle Scholar
  2. 2.
    Sin D, Hollander Z, DeMarco M, McManus B, Ng R (2015) Biomarker development for chronic obstructive pulmonary disease. From discovery to clinical implementation. Am J Respir Crit Care Med 192(10):1162–1170CrossRefGoogle Scholar
  3. 3.
    Garshick E, Grady S, Hart J, Coull B, Schwartz J, Laden F, Moy M, Koutrakis P (2018) Indoor black carbon and biomarkers of systemic inflammation and endothelial activation in COPD patients. Environ Res 165:358–364CrossRefGoogle Scholar
  4. 4.
    Singh S, Verma S, Kumar S, Ahmad M, Nischal A, Singh S, Dixit R (2018) Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol Lett 196:1–10CrossRefGoogle Scholar
  5. 5.
    Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J, Celli B, Chen R, Decramer M, Fabbri L, Frith P, Halpin D, López Varela M, Nishimura M, Roche N, Rodriguez-Roisin R, Sin D, Singh D, Stockley R, Vestbo J, Wedzicha J, Agustí A (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med 195(5):557–582CrossRefGoogle Scholar
  6. 6.
    Lee J, Kwok S, Jung S, Lee J, Lee J, Baek S, Kim E, Ju J, Park S, Kim H (2014) Role of fractalkine in the pathogenesis of primary Sjögren syndrome: increased serum levels of fractalkine, its expression in labial salivary glands, and the association with clinical manifestations. J Rheumatol 41(12):2425–2438CrossRefGoogle Scholar
  7. 7.
    Tucureanu M, Butoi E, Gan A, Stan D, Constantinescu C, Calin M, Simionescu M, Manduteanu I (2016) Amendment of the cytokine profile in macrophages subsequent to their interaction with smooth muscle cells: differential modulation by fractalkine and resistin. Cytokine 83:250–261CrossRefGoogle Scholar
  8. 8.
    Jiang J, Luo Y, Qin W, Ma H, Li Q, Zhan J, Zhang Y (2017) Electroacupuncture suppresses the NF-κB signaling pathway by upregulating cylindromatosis to alleviate inflammatory injury in cerebral ischemia/reperfusion rats. Front Mol Neurosci 10:363CrossRefGoogle Scholar
  9. 9.
    Donohue M, Cain K, Zierath D, Shibata D, Tanzi P, Becker K (2012) Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke 43(9):2300–2306CrossRefGoogle Scholar
  10. 10.
    Su Y, Chang H, Sun S, Liao C, Wang L, Ko J, Chang J (2018) Differential impact of CX3CL1 on lung cancer prognosis in smokers and non-smokers. Mol Carcinog 57(5):629–639CrossRefGoogle Scholar
  11. 11.
    Xiong Z, Leme A, Ray P, Shapiro S, Lee J (2011) CX3CR1 + lung mononuclear phagocytes spatially confined to the interstitium produce TNF-α and IL-6 and promote cigarette smoke-induced emphysema. J Immunol 186(5):3206–3214CrossRefGoogle Scholar
  12. 12.
    McComb J, Ranganathan M, Liu X, Pilewski J, Ray P, Watkins S, Choi A, Lee J (2008) CX3CL1 up-regulation is associated with recruitment of CX3CR1 + mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema. Am J Pathol 173(4):949–961CrossRefGoogle Scholar
  13. 13.
    Zhang J, Patel J (2010) Role of the CX3CL1–CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med 3(3):233–244Google Scholar
  14. 14.
    Sng J, Prazakova S, Thomas P, Herbert C (2017) MMP-8, MMP-9 and neutrophil elastase in peripheral blood and exhaled breath condensate in COPD. COPD 14(2):238–244CrossRefGoogle Scholar
  15. 15.
    Yanagawa M, Hata A, Honda O, Kikuchi N, Miyata T, Uranishi A, Tsukagoshi S, Tomiyama N (2018) Subjective and objective comparisons of image quality between ultra-high-resolution CT and conventional area detector CT in phantoms and cadaveric human lungs. Eur Radiol 28(5):2159–2168CrossRefGoogle Scholar
  16. 16.
    Galbán C, Han M, Boes J, Chughtai K, Meyer C, Johnson T, Galbán S, Rehemtulla A, Kazerooni E, Martinez F, Ross B (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18(11):1711–1715CrossRefGoogle Scholar
  17. 17.
    Gevenois P, de Maertelaer V, De Vuyst P, Zanen J, Yernault J (1995) Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 152(2):653–657CrossRefGoogle Scholar
  18. 18.
    Zhou Z, Zhou A, Zhao Y, Duan J, Chen P (2018) A comparison of the assessment of health status between CCQ and CAT in a Chinese COPD clinical population: a cross-sectional analysis. Int J Chronic Obstr Pulm Dis 13:1675–1682CrossRefGoogle Scholar
  19. 19.
    Hou H, Wang H, Cheng S, Chen Y, Lu K, Yu C (2018) MMP-12 activates protease activated receptor (PAR)-1, upregulates placenta growth factor and leads to pulmonary emphysema. Am J Physiol Lung Cell Mol Physiol 315(3):432–442CrossRefGoogle Scholar
  20. 20.
    Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K (2005) Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 25(4):640–646CrossRefGoogle Scholar
  21. 21.
    Lee S, Ro H, In H, Choi J, Kim M, Lee J, Hong S, Lee S (2018) Fisetin inhibits TNF-α/NF-κB-induced IL-8 expression by targeting PKCδ in human airway epithelial cells. Cytokine 108:247–254CrossRefGoogle Scholar
  22. 22.
    Wakita H, Yanagawa T, Kuboi Y, Imai T (2017) E6130, a novel CX3C chemokine receptor 1 (CX3CR1) modulator, attenuates mucosal inflammation and reduces CX3CR1 leukocyte trafficking in mice with colitis. Mol Pharmacol 92(5):502–509CrossRefGoogle Scholar
  23. 23.
    Rius C, Company C, Piqueras L, Cerdá-Nicolás J, González C, Servera E, Ludwig A, Morcillo E, Sanz M (2013) Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 68(2):177–186CrossRefGoogle Scholar
  24. 24.
    Ogawa E, Nakano Y, Ohara T, Muro S, Hirai T, Sato S, Sakai H, Tsukino M, Kinose D, Nishioka M, Niimi A, Chin K, Paré P, Mishima M (2009) Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax 64(1):20–25CrossRefGoogle Scholar
  25. 25.
    Kim C, Ko Y, Kim S, Yoo H, Lee J, Rhee C, Lee J, Lee J, Kim T, Lim S, Yoo K, Seo J, Oh Y, Lee S, Park Y (2018) Urinary desmosine is associated with emphysema severity and frequent exacerbation in patients with COPD. Respirology 23(2):176–181CrossRefGoogle Scholar
  26. 26.
    Wei X, Ma Z, Yu N, Ren J, Jin C, Mi J, Shi M, Tian L, Gao Y, Guo Y (2018) Risk factors predict frequent hospitalization in patients with acute exacerbation of COPD. Int J Chronic Obstr Pulm Dis 13:121–129CrossRefGoogle Scholar
  27. 27.
    Mohamed Hoesein F, Zanen P, de Jong P, van Ginneken B, Boezen H, Groen H, Oudkerk M, de Koning H, Postma D, Lammers J (2013) Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study. Respir Res 14:55CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Respiratory MedicineThe First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anPeople’s Republic of China
  2. 2.Department of Respiratory MedicineThe Affiliated Hospital of Yan’an UniversityYan’anPeople’s Republic of China

Personalised recommendations